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Abstract
Background: This study was designed to investigate the impact of liver cirrhosis due to chronic hepatitis C virus
(HCV) infection on the disease-free and overall survival of ovarian cancer patients undergoing a standard primary
operation followed by standard chemotherapy. Attainment of the operative goals, intra- and postoperative events,
possible complications under chemotherapy necessitating the termination of treatment, and the impact of ovarian
cancer treatment on liver function were assessed.
Methods: This was a prospective observational study that included only patients with primary epithelial ovarian
cancer. Only patients with Child-Turcotte-Pugh classification class A disease were recruited. Patients were divided
into two groups according to whether they had liver cirrhosis. All the patients underwent primary debulking
surgery followed by 6 cycles of chemotherapy, and were followed-up for 24 months after chemotherapy was
completed.
Results: We recruited 77 patients, 19 of whom had liver cirrhosis. There were no significant differences between
patients with or without liver cirrhosis with respect to tumor stage, histopathological type, tumor grade, or optimal
operative debulking. There was no registered liver dysfunction-related mortality in the follow-up period, and there
were no statistically significant differences between the groups with respect to disease-free or overall survival (p = 0.719
and p = 0.524, respectively).
Conclusion: From the results of this study, we conclude that compensated liver cirrhosis (Child-Turcotte-Pugh class A)
due to chronic HCV infection affects neither the disease-free nor the overall survival of ovarian cancer patients, regardless
of their stage. This study shows that it is possible to treat ovarian cancer patients with cirrhosis caused by HCV infection
the same as any other patient; treatment does not have to be adjusted as long as the patients have Class A disease.
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Background
Ovarian cancer is the second most common genital can-
cer in women and has the highest mortality of all
gynecological malignancies in developed countries [1].
In developing countries, ovarian cancer is the third most
prevalent malignancy, and has the second highest
mortality of all gynecological cancers [1]. Treatment of
ovarian cancer consists of surgery aimed at complete
tumor resection followed by 6 chemotherapy cycles of a
combination of carboplatin and paclitaxel [2]. However,
a number of other therapy regimens, including neoadju-
vant chemotherapy followed by interval debulking for
advanced primarily inoperable cases, have proven to be
at least as effective [3].
Although the combined incidence rate of all cancers
is nearly twice as high in more developed than in less
developed countries in both men and women, the
mortality rates of these cancers are only 8–15 %
* Correspondence: amr.soliman@uni-oldenburg.de
4Universitätsklinik für Gynäkologie und Geburtshilfe, Klinikum Oldenburg,
Fakultät für Medizin und Gesundheitswissenschaften, Universität Oldenburg,
Rahel-Straus-Straße 10, 26133 Oldenburg, Germany
5Department of Obstetrics and Gynecology, University of Alexandria,
Alexandria, Egypt
Full list of author information is available at the end of the article
© 2015 Refky et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Refky et al. BMC Cancer  (2015) 15:754 
DOI 10.1186/s12885-015-1805-9
higher in more developed countries [1]. This discrep-
ancy reflects the availability of advanced therapeutic
technologies in more developed countries and the
worse general condition of cancer patients in less
developed countries.
The increasing life expectancy in many countries
means that age, the presence of co-morbidities, and the
patient’s general condition and performance status are
increasingly important prognostic factors for survival
[4–6], and health professionals have to care for many
elderly ovarian cancer patients presenting with co-
morbidities that may affect their treatment decisions [7].
Chronic hepatitis C virus (HCV) infection is a major
burden on the health system in many developing coun-
tries including Egypt [8], where its prevalence in the 15–
59 years old age group is as high as 14.7 % [9, 10], and
thus considered to be the highest in the world [11, 12].
Approximately 50–85 % of patients with HCV infection
develop chronic hepatitis, and of these, 20–30 % develop
cirrhosis over a 20- to 30-year period [13]. HCV liver
cirrhosis can be asymptomatic (compensated), present-
ing only as mild fatigue and subtle laboratory liver pro-
file changes that are accidently discovered during a
routine laboratory workup. However, it can also present
in a decompensated, symptomatic form that reduces life
expectancy. These symptoms can include ascites, vari-
ceal hemorrhage, encephalopathy, and hepato-renal syn-
drome, or it can develop over a number of years into
hepatocellular carcinoma (HCC) [14]. Patients with liver
cirrhosis currently undergo more surgical procedures
compared to 20 or 30 years ago to because of improved
post-operative survival secondary to improved methods
of diagnosis and evolving therapies. Up to 10 % of cir-
rhotic patients might undergo surgery in the last 2 years
of their lives [15]. Operating on a chronic liver patient
poses a risk of liver injury due to perioperative drug ad-
ministration along with alterations in hepatic blood flow
caused by hemodynamic changes during anesthesia and
surgery [16]. A widely acceptable tool to assess the peri-
operative risk in relation to liver function and the pa-
tient’s general condition is the Child-Turcotte-Pugh
classification (Tables 1 and 2) [17]. Patients with good
hepatic reserve, no ascites, and a good nutritional status
(Child class A) can withstand surgery, whereas those
with jaundice, low serum albumin, ascites, and muscle
wasting have a higher operative mortality and postopera-
tive morbidity [18].
This, however, was not validated in patients with epi-
thelial ovarian cancer. The impaired liver function and
consequently increased perioperative risk in these pa-
tients may be worsened by the primary operative treat-
ment and the consequent adjuvant chemotherapy that
are recommended as standard of care for epithelial ovar-
ian cancer patients. As stated above, presence of comor-
bidities is an important prognostic factor when dealing
with epithelial ovarian cancer patients. Liver function
impairment, even if mild in Child class A patients, may
have an impact on survival and prognosis of ovarian
cancer patients. This was not previously investigated in
published studies.
This study investigates the prognosis of epithelial ovar-
ian cancer patients, in terms of overall and disease-free
survival, who concomitantly suffer from liver cirrhosis
due to chronic HCV infection and are class A according
to Child-Turcotte-Pugh classification. The achievement
of operative goals, intra- and postoperative adverse
events, possible chemotherapy-related complications
leading to the termination of treatment, and the impact
of ovarian cancer treatment on liver function in these
patients are also assessed.
Methods
This is a prospective observational cohort study con-
ducted in the Oncological Surgery Department, Oncol-
ogy Center Mansura University, Mansura, Egypt. The
study was approved by the institutional review board;
the Ethics Committee, Faculty of Medicine, University of
Mansura. (approval number 256/2010). The patient co-
hort included patients suffering from epithelial ovarian
cancer, a subgroup of which suffers from liver cirrhosis
due to chronic HCV infection and are exclusively classi-
fied as Child class A. All patients presenting with
Table 1 Child-Turcotte-Pugh Scores with respect to different clinical parameters [17]
1 point 2 points 3 points
Total bilirubin, μmol/L (mg/dL) <34 (<2) 34–50 (2–3) >50 (>3)
Serum albumin, g/dL >3.5 2.8–3.5 <2.8
INR <1.7 1.71–2.30 >2.30
Ascites None Mild Moderate to severe
Hepatic encephalopathy None Grade I-II (or suppressed with medication) Grade III-IV (or refractory)
Table 2 Child-Turcotte-Pugh Scores with respect to different
clinical parameters [17]
Points Class One-year survival Two-year survival
5–6 A 100 % 85 %
7–9 B 85 % 57 %
10–15 C 41 % 37 %
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symptoms consistent with ovarian cancer, and who were
being prepared for a primary explorative laparotomy be-
tween February 2011 and February 2013, gave signed, in-
formed consent for participation. The final decision as
to whether a patient should be included in the study was
based on the final histopathology report. Only patients
with epithelial primary ovarian cancer and a perform-
ance status of 0–2 according to the Eastern Cooperative
Oncology Group classification were included [19]. Pa-
tients assigned to receive neoadjuvant treatment were
excluded from this study, as were those younger than
18 years or older than 75 years. A routine preoperative
abdominal and pelvic computed tomography scan was
obtained. This was also used to identify patients with
liver cirrhosis. CT criteria suggestive of liver cirrhosis in-
clude; heterogeneous liver parenchyma, surface nodular-
ity in addition to the presence of signs of early portal
hypertension, namely clinically silent small esophageal
varices and caudate lobe hypertrophy [20, 21]. A labora-
tory liver profile was obtained, which included serum al-
bumin, transaminases, and bilirubin levels, and the
international normalization ratio (INR). Patients with
liver cirrhosis from causes other than HCV infection
were excluded from the study, as were liver cirrhosis pa-
tients with a Child-Turcotte-Pugh classification other
than class A. After obtaining the final histopathology re-
port, primary epithelial ovarian cancer patients were re-
cruited for the study and divided into two groups: those
with hepatic cirrhosis Child class A due to chronic HCV
infection (group A) and those without cirrhosis or any
detectable hepatic disorder (group B). All the patients
received the institutional standard therapy for ovarian
cancer, namely primary operative cytoreduction includ-
ing explorative laparotomy, abdominal hysterectomy
with bilateral salpingo-ovariectomy, omentectomy, peri-
toneal sampling, pelvic and para-aortic systematic
lymphadenectomy, and eventually tumor debulking in
patients with advanced stage disease through visceral
organ resection and ultimately liver resection, as recom-
mended by the German workgroup for gynecological on-
cology (AGO) for treating epithelial ovarian cancer [2].
All the patients received 6 cycles of chemotherapy post-
operatively using combined paclitaxel (175 mg/m2 body
surface area) and carboplatin (area under the curve
[AUC], 5), both administered intravenously every 3 weeks
as a standard adjuvant therapy, as recommended by the
AGO [2]. Treatment was considered complete after the
completion of chemotherapy. Operative data (operative
time, amount of intra operative bleeding, visceral organ
resection, liver resection, intraoperative urological and
vascular complications and length of stay in the inten-
sive care unit), the postoperative liver profile, and the
development of postoperative complications were all re-
corded. Urological complications refer to bladder and/or
ureteral injuries that are repaired intraoperatively. Vas-
cular complications refer to venous or arterial injuries to
the pelvic vessels and/or the vena cava or aorta that
were immediately repaired intra-operatively with no fur-
ther consequences. All the patients were then followed-
up for 24 months after completing chemotherapy. Pa-
tients lost to follow-up were excluded from the statistical
analysis. Follow-up data (late postoperative complica-
tions, chemotherapy complications, chemotherapy inter-
ruption, recurrence, liver function, and liver function-
related complications) were also registered.
The sample size of the cohort (77) was calculated at a
study power of 80 % and a level of significance at 5 %.
The obtained data was tabulated using Microsoft Excel
(Microsoft Corporation, Redmond, WA, USA) and ana-
lyzed using SPSS for Microsoft Windows, version 21.0
(SPSS, Chicago, IL, USA). The normality of data was
first tested with the one-sample Kolmogorov-Smirnov
test. Qualitative data are described using the number
and percent. Continuous variables are presented as the
mean ± standard deviation (SD) for parametric data, and
the range and the median for non-parametric data. All
the following tests are two tailed. Associations between
categorical variables were tested using the Chi-square
test, and groups were compared using the Student t-test
(parametric data) or the Mann–Whitney U test (non-
parametric data). The Kaplan-Meier test was used for
survival analysis and the statistical significance of differ-
ences between curves was determined using the log-
rank test. For all of the statistical tests, the threshold of
significance was set at 5 % (p-value). Differences were
considered significant if the probability of error was less
than 5 % (p < 0.05). The confidence interval (CI) was set
at 95 % for all tests of significance concerning disease-
free as well as overall survival.
Results
We recruited 77 patients who met the inclusion cri-
teria between February 2011 and February 2013.
Nineteen patients (24.7 %) had liver cirrhosis due to
HCV infection (group A) while the other 58 patients
(76.3 %) were free from any documented liver disease
(group B). There was no significant difference be-
tween the groups with respect to age (p = 0.623); the
median age was 58 years (range, 49–69 years) in
group A and 57 years (range, 47–68 years) in group
B. There were also no significant differences between
the groups with respect to tumor stage, histopatho-
logical type, tumor grade, or optimal operative
debulking (as defined by the AGO [2]) (Table 3).
Likewise, both groups showed similar urological and
vascular operative complications. None of the patients
underwent liver resection. Liver capsule resection was
not considered liver resection per se and was instead
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included with visceral organ resection. Visceral organ
resection in turn refers to a range of procedures in-
cluding intestinal resection with re-anastomosis or
with colostomy/ileostomy, and partial bladder resec-
tion with or without ureteric re-implantation. The
mean length of stay in the intensive care unit was
not significantly different between the two groups
(Table 4), and neither was the incidence of postopera-
tive complications such as intestinal fistula or leakage,
wound complications, lymphorrhea or lymphocysts, or
thrombo-embolic events (Table 5). Preoperative serum
albumin level was statistically significant lower in
group A than in group B, [mean ± SD in mg/dL,
group A = 3.59 ± 0.28, group B = 3.96 ± 0.39, (group A
3.2–3.76, group B 3.57–4.46, CI = 95 %), p ≤ 0.001].
Postoperative levels of serum albumin in group B
were statistically significant lower than preoperative
levels, [mean ± SD in mg/dL, preoperative = 3.96 ±
0.39, postoperative = 3.63 ± 0.46, (group A 3.56–4.39,
group B 3.13–4.01, CI = 95 %), p ≤ 0.001]. Serum bili-
rubin level was statistically significant higher postop-
eratively in group A in comparison with group B
[mean ± SD in mg/dL, group A = 1.11 ± 0.21, group B
= 0.97 ± 0.16, (group A 0.99–1.29, group B 0.89–1.11,
CI = 95 %) p = 0.004] and in comparison with pre-
operative levels in group A [mean ± SD in mg/dL,
preoperative =0.963 ± 0.11, postoperative = 1.11 ± 0.21,
(preoperative 0.871–0.999, postoperative 0.981–1.23,
CI = 95 %) p = 0.008].
AST, ALT and INR values did not statistically signifi-
cant differ between both groups neither pre- nor post-
operatively. These findings had no further significant im-
pact on completion of treatment.
Only 1 patient had to discontinue chemotherapy in
group A, and 2 in group B, due to intolerance to adverse
reactions (neuropathy), although this difference was not
statistically significant (p = 0.89).
During the follow-up period, 2 patients in group A
and 8 in group B experienced recurrences, with 1
cancer-related death in group A and 7 in group B,
although these were not related to liver dysfunction.
Figures 1 and 2 show the disease-free and overall sur-
vival curves in both groups, respectively, using
Kaplan-Meier estimators. There were no statistically
Table 3 Comparison between the groups with respect to FIGO stage, histopathological type, tumor grade, and operative
cytoreduction
Group A [n = 19 (24.7 %)] Group B [n = 58 (75.3 %)]
Tumor stage (FIGO) I 9 I 19 p = 0.35
II 5 II 10
III 5 III 27
IV 0 IV 2
Histopathological type Serous 17 48 p = 0.707
Mucinous 1 6
Clear cell 1 4
Tumor grade G1 5 G1 18 p = 0.613
G2 3 G2 11
G3 11 G3 29
Operative cytoreduction R0 14 R0 41 p = 0.802
R1 and/or R2 5 R1 and/or R2 17
Table 4 Intra-operative procedures and complications, and the length of stay in the intensive care unit in each group
Group A [n = 19 (24.7 %)] Group B [n = 58 (75.3 %)]
Operative time, minutes (mean ± SD) 202.42 ± 66.09 209.16 ± 60.03 p = 0.680
Intra-operative bleeding, ml (mean ± SD) 463 ± 76 485 ± 85 p = 0.49
Urological complications 1 5 p = 0.63
Vascular complications 2 4 p = 0.6
Visceral organs resection 4 20 p = 0.62
Length of stay in intensive care unit, days (median and range) 4 4 p = 0.229
range 3–7 range 1–5
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significant differences between the groups with re-
spect to disease-free or overall survival [disease-free
survival was in group A 19.9–26.7 months (CI 95 %)
and in group B 19.4–26.1 months (CI 95 %), while
overall survival was in group A 21.6–25.7 months (CI
95 %) and in group B 21.1–25.1 months (CI 95 %),
(p = 0.710 and p = 0.524, respectively)].
Discussion
This is the first prospective study to investigate the
relationship between liver cirrhosis caused by HCV
infection and ovarian cancer. Our findings revealed
that there was no significant impact of liver cirrhosis
due to HCV infection on the disease-free or overall
survival of ovarian cancer patients. Patients with liver
cirrhosis showed some significant but minimal differ-
ences in their laboratory parameters that did not
affect their liver condition or their capacity to
complete adjuvant chemotherapy.
Our findings are in agreement with the published
outcomes of liver cirrhosis patients with Child class
A cirrhosis who underwent operative procedures. In
those patients, the operative risk of elective surgery
was moderate and surgical indications were not
altered by the presence of cirrhosis [22, 23]. Our
results confirm this outcome in ovarian cancer
patients.
It seems that ovarian cancer patients with liver Child
class A cirrhosis due to chronic HCV infection perform
better than ovarian cancer patients with diabetes melli-
tus who generally have a worse prognosis compared to
non-diabetic patients [6, 24, 25]. Ovarian cancer patients
with liver cirrhosis have a better performance status than
ovarian cancer patients with other co-morbidities that
have a negative impact on survival [26, 27] and that af-
fected the treatment decisions made by health care pro-
fessionals, even leading to the discontinuation of
treatment in some cases [28].
This study was limited by the small number of
recruited patients and the extent to which laboratory
liver parameters could be investigated. These limita-
tions are attributed to the limited resources of the
institution and the country in which the study took
place.
Table 5 Comparison of postoperative complications between the groups
Group A [n = 19 (24.7 %)] Group B [n = 58 (75.3 %)]
GIT fistula or leakage 1 5 p = 0.63
Wound complications 1 7 p = 0.39
Lymphorrhea or lymphocyst 0 2 p = 0.41
Thrombo-embolic events 1 3 p = 1
Fig. 1 Kaplan-Meier curve showing disease-free survival in group A and B (p = 0.719, CI = 95 %). (a = group A, with liver cirrhosis. b = group B, with
no liver cirrhosis)
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Conclusions
From the results of this study, we conclude that com-
pensated liver cirrhosis (Child-Turcotte-Pugh class A)
due to chronic HCV infection affects neither the
disease-free nor the overall survival of ovarian cancer
patients, regardless of their stage. This study shows that
it is possible to treat ovarian cancer patients with cirrho-
sis caused by HCV infection the same as any other pa-
tient; treatment does not have to be adjusted as long as
the patients have Class A disease.
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